retatrutide phase 2 trial 2: Type Diabetes Weight Loss and Key Findings – Bolt Pharmacy Retatrutide - Wikipedia

The rationale is that glucagon also increases energy expenditure and promotes hepatic fat mobilization, so a molecule that combines glucagons metabolic-rate effect with GLP-1/GIPs appetite-and-glucose control can, in principle, drive weight loss from both sides of the energy-balance equation at once

The combination of pharmacological appetite suppression with behavioral nutrition guidance produces synergistic effects that neither approach achieves independently

Ongoing studies are evaluating cardiovascular outcomes with tirzepatide in populations with overweight/obesity and T2D (SURPASS-CVOT) and in those with obesity but without diabetes (SURMOUNT-MMO) [28, 29]

Diabetes Spectrum : A Publication of the American Diabetes Association, 30 (3), 153-156